Shiga toxin 1 elicits diverse biologic responses in mesangial cells

Kidney International

Volumn 54, Issue 4, 1998, Pages 1117-1127

  Simon, Matthias ^a,b   Cleary, Thomas G ^d   Hernandez, James D ^d   Abboud, Hanna E ^c  

^a Deutsche Forschungsgemeinschaft   (Germany)

^b NATIONAL KIDNEY FOUNDATION   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d NONE

Author keywords

Cell injury; Edema; Glomerulosclerosis; Glycosphingolipid globotriaosylceramide; Hemolytic uremic syndrome; Monocyte chemotactic protein 1; Protein synthesis inhibition

Indexed keywords

GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; SHIGA TOXIN;

ARTICLE; CELL DAMAGE; CELL VIABILITY; EDEMA; ENDOTHELIUM CELL; GLOMERULOSCLEROSIS; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY FUNCTION; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RIBOSOME SUBUNIT;

EID: 0031688091     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00085.x     Document Type: Article

References (51)

1. GASSER C, GAUTIER E, STECK A, SIEBENMANN RE, DECHSLIN R: Hämolytisch-urämisches Syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 85:905-909, 1955
2. REMUZZI G, RUGGENENTI P: The hemolytic uremic syndrome. Kidney Int 47:2-19, 1995
3. KARMALI MA, STEELE BT, PETRIC M, LIM C: Sporadic cases of hemolytic-uremic syndrome associated with faecal verotoxin and cytotoxin producing Escherichia coli in stools. Lancet 1:619-620, 1983
4. KARMALI MA, PITRIC M, LIM C, FLEMING PC, ARBUS GS, LIOR H: The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775-782, 1985
5. RILEY LW, REMIS RS, HELGERSON SD, MCGEE HB, WELLS JG, DAVIS BR, HEBERT RJ, OLCOTT ES, JOHNSON LM, HARGRETT NT, BLAKE PA, CONEN ML: Hemorrhagic colitis associated with a rare Escherichia coli O157:H7 serotype. N Engl J Med 308:681-685, 1983
6. VAN DE KAR NC, ROELOFS HG, MUYTJENS HL, TOLBOOM JJ, ROTH B, PROESMANS W, REITSMA-BIERENS WC, WOLFF ED, KARMALI MA, CHART H, MONNENS LA: Verocytotoxin-producing Escherichia coli infection in hemolytic uremic syndrome in part of western Europe. Eur J Pediatr 155:592-595, 1996
7. TOZZI AE, NICCOLINI A, CAPRIOLI A, LUZZI I, MONTINI G, ZACCHELLO G, GIANVITI A, PRINCIPATO F, RIZZONI G: A community outbreak of haemolytic-uraemic syndrome in children occurring in a large area of northern Italy over a period of several months. Epidemiol Infect 113:209-219, 1994
8. ROWE PC, ORRBINE E, OGBORN M, WELLS GA, WINTHER W, LIOR H, MANUEL D, MCLAINE PN: Epidemic Escherichia coli O157:H7 gastroenteritis and hemolytic-uremic syndrome in a Canadian inuit community: Intestinal illness in family members as a risk factor. J Pediatr 124:21-26, 1994
9. PETRIC M, KARMALI MA, RICHARDSON S, CHEUNG R: Purification and biological properties of Escherichia coli verocytotoxin. FEMS 41:63-68, 1987
10. SANDVIG K, OLSNES S, BROWN JE, PETERSEN OW, VAN DEURS B: Endocytosis from coated pits of Shiga toxin: A glycolipid-binding protein from Shigella dysenteriae I. J Cell Biol 108:1331-1343, 1989
11. OBRIG TG, MORAN TP, BROWN JE: The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244:287-294, 1987
12. LINGWOOD CA: Verotoxins and their glycolipid receptors. Adv Lipid Res 25:189-211, 1993
13. LINDBERG AA, BROWN JE, STROMBERG N, WESTLING-RYD M, SCHULTZ JE, KARLSSON KA: Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem 262:1779-1785, 1987
14. LINGWOOD CA, LAW H, RICHARDSON S, PETRIC M, BRUNTON JL, DE GRANDIS S, KARMALI M: Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 262: 8834-8839, 1987
15. BOYD B, LINGWOOD C: Verotoxin receptor glycolipid in human renal tissue. Nephron 51:207-210, 1989
16. ROBINSON LA, HURLEY RM, LINGWOOD C, MATSELL DG: Escherichia coli verotoxin binding to human pediatric glomerular mesangial cells. Pediatr Nephrol 9:700-704, 1995
17. OBRIG TG, DEL VECCHIO PJ, BROWN JE, MORAN TP, ROWLAND BM, JUDGE TK, ROTHMAN SW: Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 56:2373-2378, 1988
18. LOUISE CB, OBRIG TG: Shiga toxin-associated hemolytic uremic syndrome: Combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun 60:1536-1543, 1992
19. LOUISE CB, OBRIG TG: Shiga toxin-associated hemolytic-uremic syndrome: Combined cytotoxic effects of Shiga toxin, interleukin-1beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 59:4173-4179, 1991
20. OBRIG TG, LOUISE CB, LINGWOOD CA, BOYD B, BARLEY-MALONEY L, DANIEL TO: Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 268:15484-15488, 1993
21. VAN SETTEN PA, VAN HINSBERGH VW, VAN DER VELDEN TJ, VAN DE KAR NC, VERMEER M, MAHAN JD, ASSMANN KJ, VAN DEN HEUVEL LP, MONNENS LA: Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 51:1245-1256, 1997
22. CHURG J, GOLDSTEIN MH, BERNSTEIN J: Thrombotic microangiopathy including hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and postpartum renal failure, in Renal Pathology (vol 2), edited by TISHER CC, BRENNER BM, Philadelphia, J.B. Lippincott Company, 1989, pp 1081-1113
23. HEPTINSTALL RH: Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and systemic sclerosis (systemic scleroderma), in Pathology of the Kidney (vol 2), edited by HEPTINSTALL RH, Boston, Little, Brown & Co., 1983, pp 1163-1233
24. PRADO D, CLEARY TG, PICKERING LK, ERICKSON CD, BARTLETT AV, DUPONT HL, JOHNSON PC: The relation between production of cytotoxin and clinical features in shigellosis. J Infect Dis 154:149-155, 1986
25. SILVER BJ, JAFFER FE, ABBOUD HE: Interferon-γ-mediated activation of STAT1α regulates growth factor-induced mitogenesis. J Clin Invest 98:1218-1230, 1996
26. SHULTZ PJ, DICORLETTO PE, SILVER BJ, ABBOUD HE: Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 255:F674-F684, 1988
27. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
28. GRANDALIANO G, VALENTE AJ, ABBOUD HE: A novel biologic activity of thrombin: Stimulation of monocyte chemotactic protein production. J Exp Med 179:1737-1741, 1994
29. ROBINSON LA, HURLEY RM, LINGWOOD C, MATSELL DG: Escherichia coli verotoxin binding to human paediatric glomerular mesangial cells. Pediatr Nephrol 9:700-704, 1995
30. LOUISE CB, OBRIG TG: Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvasc Res 47:377-387, 1994
31. VAN DE KAR NC, MONNENS LA, KARMALI MA, VAN HINSBERGH VW: Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80:2755-2764, 1992
32. 3, is required but not sufficient to confer sensitivity to Shiga toxin. J Infect Dis 169:538-546, 1994
33. SANDVIG K, RYD M, GARRED O, SCHWEDA E, HOLM PK, VAN DEURS B: Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol 126:53-64, 1994
34. SANDVIG K, GARRED O, VAN HELVOORT A, VAN MEER G, VAN DEURS B: Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells. Mol Biol Cell 7:1391-1404, 1996
35. KIARASH A, BOYD B, LINGWOOD CA: Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J Biol Chem 269:11138-11146, 1994
36. GARRED O, DUBININA E, HOLM PK, OLSNES S, VAN DEURS B, KOZLOV JV, SANDVIG K: Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp Cell Res 218:39-49, 1995
37. GARRED O, VAN DEURS B, SANDVIG K: Furin-induced cleavage and activation of Shiga toxin. J Biol Chem 270:10817-10821, 1995
38. VAN SETTEN PA, VAN HINSBERG VWM, VAN DEN HEUVEL LPWJ, VAN DER VELDEN TJAN, VAN DE KAR NCAJ, KREBBERS RJM, KARMALI MA, MONNENS LAH: Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: Evidence for two distinct mechanisms. J Am Soc Nephrol 8:1877-1888, 1997
39. ROVIN BH, YOSHIMURA T, TAN LT: Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J Immunol 148:2148-2153, 1992
40. SATRIANO JA, HORA K, SHAN Z, STANLEY ER, MORI T, SCHLONDORFF D: Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-γ, tumor necrosis factor-α, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol 150:1971-1978, 1993
41. LEONARD EJ, YOSHIMURA T: Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11:97-101, 1990
42. VAN SETTEN P, VAN DEN HEUVEL L, VAN HINSBERGH V, PREIJERS F, MONNENS L: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and iInterleukin-8 (IL-8) are elevated in HUS patients. (abstract) VTEC '97, 3rd International Symposium and Workshop on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections, June 22-26, Baltimore, 1997, p 83
43. HAREL Y, SILVA M, GIROIR B, WEINBERG A, CLEARY TG, BEUTLER B: A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 92:2110-2116, 1993
44. BARRETT TJ, POTTER ME, STROCKBINE NA: Evidence for participation of the macrophage in Shiga-like toxin II-induced lethality in mice. Microbiol Pathog 9:95-103, 1990
45. VAN SETTEN PA, MONNENS LA, VERSTRATEN RG, VAN DEN HEUVEL LP, VAN HINSBERGH VW: Effects of verocytotoxin-1 on nonadherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release. Blood 88:174-183, 1996
46. RAMEGOWDA B, TESH VL: Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect Immun 64:1173-1180, 1996
47. ABBOUD HE: Resident glomerular cells in glomerular injury: Mesangial cells. Semin Nephrol 11:304-311, 1991
48. GIANANTONIO CA: Hemolytic-uremic syndrome, in Pediatric Kidney Disease edited by EDELMANN CM JR, Boston, Little, Brown & Co., 1978, pp 724-736
49. VAN DYCK M, PROESMANS W, DEPRAETERE JP: Hemolytic uremic syndrome in chidhood: Renal function ten years later. Clin Nephrol 29:109-112, 1988
50. 99mTcDtpa plasma slope clearance. Clin Nephrol 32:217-220, 1989
51. GAGNADOUX M-F, HABIB R, GUBLER M-C, BACRI JL, BROYER M, KLEINKNECHT C: Long-term (15-25 years) prognosis of childhood hemolytic-uremic syndrome (HUS). (abstract) J Am Soc Nephrol 4:275, 1993